SOLICITATION NOTICE
Q -- Molecular Analysis of Fixed Paraffin-Embedded (FFPE) Tonsil Tumors
- Notice Date
- 8/13/2012
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120114-LG
- Archive Date
- 9/12/2012
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6070, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Infections and Immunoepidemiology Branch (IIB), plans to procure on a sole source basis services from Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarton, Oxford, OX51PF, United Kingdom, for molecular analysis of fixed paraffin-embedded (FFPE) tonsil tumors. This acquisition will be processed in accordance with simplified acquisition procedures in FAR Part 13.106 (b)(1). The North American Industry Classification System code is 541380 the business size standard is $12.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Division of Cancer Epidemiology and Genetics (DCEG) is an intramural research program of the National Cancer Institute (NCI) that conducts population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The Infections and Immunoepidemiology Branch (IIB) conducts multidisciplinary studies of carefully selected domestic and foreign populations, with the goal of clarifying the relationship of infectious agents, especially viruses, to human cancer and other conditions. The IIB is comparing chromosomal aberrations of HPV positive tonsil tumors with cervical pre-cancerous lesions (CIN 3) and invasive cancer. The study will be conducted using tonsil tumor specimens from the Surveillance Epidemiology End Result study Residual Tissue Repository (SEER-RTR) study as well as CIN3 and cancer cases from the Study to Understand Cervical Cancer Endpoints and Early Determinants (SUCCEED) that were previously characterized using the CGH assay. The purpose of this requirement is to conduct molecular analyses on 140 formalin fixed paraffin-embedded (FFPE) tonsil tumors previously characterized for HPV DNA from the Surveillance Epidemiology End Result study Residual Tissue Repository (SEER-RTR). From the same cases, extracted DNA will be prepared for array CGH using the Agilent platform. Oxford Gene Technology is the only known contractor that can fulfill the requirements of this project. A primary objective of this study is to compare chromosomal alterations of tonsillar tissue with data previously collected from CIN 3 and cervical cancer patients in the SUCCEED study using the contractor designated above as part of a separate contract. Therefore, to assure accurate and valid comparisons of our results with previously collected data, it is imperative that Oxford Gene Technologies conducts this CGH testing and data collection. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on August 28, 2012. No electronic capability statements will be accepted (i.e. email or fax) an original and one copy must be sent to the NCI Office of Acquisition to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Laura Glockner, Contract Specialist at laura.glockner@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through SAM.gov. No collect calls will be accepted. Please reference solicitation number NCI-120114-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120114-LG/listing.html)
- Record
- SN02836698-W 20120815/120813235722-ff840e39e5de362f9172fffb0841988d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |